HOVANA is a digital biology company focused on developing precision medicines that target cellular dysfunction, a key factor in immunology and neuroscience disorders. By utilizing advanced cellular reprogramming techniques, HOVANA aims to restore human health and improve patient outcomes in these critical areas.
Funding
Funding not disclosed
Founders
Product
Problem
Many immunology and neuroscience disorders are driven by cellular dysfunction, which current treatments often fail to address at the cellular level. Existing therapies may not effectively restore normal cellular function, leading to suboptimal patient outcomes.
Solution
HOVANA is developing precision medicines that target the root causes of cellular dysfunction in immunology and neuroscience disorders. The company leverages advanced cellular reprogramming techniques and digital biology to create a new class of therapeutics. These precision medicines aim to restore healthy cellular function, leading to improved patient outcomes. HOVANA's approach combines insights into cellular reprogramming with capabilities in drug discovery, clinical research, and digital science.
Target Audience
The primary target audience includes patients suffering from immunology and neuroscience disorders, as well as clinicians and researchers in these fields.
Features
- Focus on cellular reprogramming to address cellular dysfunction
- Pipeline of precision medicines for immunology and neuroscience disorders
- Integration of digital science and drug discovery
- Targeting the underlying causes of disease at the cellular level